Observational study on eye health in the elderly
Official title: The Proactive Ophthalmic Examination Cohort of Older Adults
Run by Zhongshan Ophthalmic Center, Sun Yat-sen University · NCT05851287 · Data updated 2026-11-12
This study is looking at how lifestyle and genetics affect eye health in older people to help understand the risks for common eye diseases like glaucoma and macular degeneration.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Zhongshan Ophthalmic Center, Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | February 20, 2023 |
| Main results expected | February 19, 2033 |
| Study ends | February 19, 2034 |
| Registry record updated | June 9, 2026 |
| Trial ID | NCT05851287 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are elderly individuals over 60 years old with normal vision and no significant ocular diseases.
✕Probably not a fit
Patients with existing ocular diseases or those who have undergone recent eye surgeries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a cohort of elderly individuals with normal vision and ocular structure to investigate the risk factors for common eye diseases such as glaucoma and age-related macular degeneration. Participants will undergo yearly examinations for at least five years to collect clinical and genomic data. The focus is on understanding how lifestyle changes and genetics impact eye health in the aging Chinese population. The findings will provide valuable insights for future clinical studies on eye diseases.
Why it matters
Potential benefit: If successful, this study could lead to better prevention and management strategies for eye diseases in the elderly.
How similar studies have gone: Other studies focusing on aging and eye health have shown promising results, indicating that this approach is supported by previous research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Aged 65 years or older Exclusion Criteria: * Unable to complete required systemic or ophthalmic examinations due to frailty, poor general health, or other physical limitations * Refusal to participate in the study
Where it's running
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Haotian Lin, M.D., Ph.D.
- Email: haot.lin@hotmail.com
- Phone: +86 13802793086
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
Autologous Serum Tears with Hyaluronate vs Standard Serum Tears for Moderate-to-Severe Dry Eye
This study tests whether adding sodium hyaluronate to autologous serum eye drops provides better relief for adults with moderate-to-severe dry eye in one eye, compared with the standard serum drops in the other eye.
-
Two approaches to repeat eyelid surgery for post-operative trichiasis
This project will try whether the newer Bevel-Rotate Advancement Procedure (B-RAP) or the standard Bilamellar Tarsal Rotation (BLTR) gives better results for people in Tanzania who need repeat surgery for post-operative trachomatous trichiasis.
-
How TRYPTYR affects quality of life and the ability to work for people with dry eye
This one-month test will see if TRYPTYR (acoltremon) eye drops help adults with chronic dry eye produce more tears, reduce symptoms, and improve their ability to do work.
-
Course of EYS-associated retinitis pigmentosa in adults from Russia and former CIS
We will follow adults with pathogenic EYS gene variants from Russia and former CIS for four years to try to find reliable vision and retinal measures for future treatments.
-
Dapagliflozin (an SGLT2 inhibitor) for slowing geographic atrophy in dry AMD
This trial will test whether taking dapagliflozin once daily can slow the growth of geographic atrophy in people aged 50 and older with dry age-related macular degeneration.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.